RRAGA/RRAGB Antibody

What are the primary applications of RRAGA/RRAGB antibodies in research?

RRAGA/RRAGB antibodies serve as valuable tools for investigating the roles of these proteins in multiple cellular processes. Primary applications include:

• Western blot (WB): For detecting and quantifying RRAGA/RRAGB expression levels in various tissue and cell types

• Immunohistochemistry (IHC-P): For visualizing protein localization in tissue sections

• Immunofluorescence (IF): For co-localization studies with other proteins

• Immunocytochemistry (ICC): For cellular localization studies

• ELISA: For quantitative protein detection

When designing experiments, researchers should consider the following application-specific dilution recommendations:

These dilutions are based on validated protocols for polyclonal antibodies such as the RRAGA Rabbit Polyclonal Antibody (CAB15134) .

What species reactivity should researchers consider when selecting RRAGA/RRAGB antibodies?

Species reactivity is a critical consideration in antibody selection. Available RRAGA/RRAGB antibodies show validated reactivity with:

• Human samples (most common)

• Mouse tissues (particularly brain samples)

• Rat tissues (brain and kidney samples)

• Pig/porcine samples

• Dog/canine samples

When working with zebrafish models, researchers should note that maternal contribution of RRAGA mRNA has been observed, which may affect experimental interpretations when studying developmental processes .

For cross-species studies, it is advisable to validate antibody performance in each species of interest, as sequence homology does not always guarantee equivalent binding affinity or specificity.

How should researchers validate RRAGA/RRAGB antibody specificity?

Proper validation of antibody specificity is essential for generating reliable research data. Recommended validation methods include:

• Positive control samples: Use tissues/cells known to express the target protein. Validated positive samples for RRAGA antibodies include:

  • 293T cell lysates

  • Mouse brain lysates

  • Rat brain and kidney lysates

• Genetic knockdown/knockout controls: Compare staining patterns between wild-type and RRAGA/RRAGB-deficient samples. Zebrafish models with RRAGA mutations (such as st77 and st110 alleles) have been generated and can serve as valuable controls .

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide before application to demonstrate binding specificity.

• Multiple antibody approach: Use antibodies targeting different epitopes of RRAGA/RRAGB to confirm findings.

• Molecular weight verification: RRAGA protein should be detected at the expected molecular weight, confirming target specificity .

How can researchers effectively investigate RRAGA's dual roles in mTORC1-dependent and mTORC1-independent pathways?

RRAGA functions in both mTORC1-dependent amino acid sensing and mTORC1-independent pathways, creating complexity in experimental design. To differentiate between these functions:

• Comparative analysis with mTOR inhibitors: Treat cells with specific mTOR inhibitors (e.g., Torin1) and compare phenotypes with RRAGA knockdown/knockout. Studies have shown that RRAGA mutants display increased expression of TFEB target genes (e.g., hexa, asah1b, bloc1s6, ctsc, mapk1, and gabarap), while mTOR inhibition with Torin1 produces different effects on these same genes .

• Co-immunoprecipitation studies: Identify RRAGA binding partners beyond the mTORC1 complex. Previous studies have identified interactions with:

  • Nucleolar protein NG132

  • Microtubule cargo adapter DYLNT

  • Hedgehog signaling protein WDR35

• Cell-specific expression approaches: Use cell-type specific promoters to express wild-type RRAGA in RRAGA-deficient backgrounds. In zebrafish models, expression of wild-type RRAGA under macrophage/microglia-specific promoters (mpeg1) rescued microglia development, whereas expression in other cell types did not, demonstrating cell-autonomous functions .

• Analyze lysosomal function: Since RRAGA regulates lysosomal function independently of mTOR, researchers should employ lysosomal activity assays alongside mTOR signaling analysis. Methods include:

  • LysoTracker staining

  • Neutral red accumulation assays

  • Expression analysis of lysosomal genes

What methodological approaches are most effective for studying RRAGA's role in CD47 regulation and immune evasion?

RRAGA has been identified as a negative regulator of CD47, a macrophage-specific immune checkpoint protein that inhibits phagocytosis. To investigate this relationship:

• CD47 degradation pathway analysis: Track CD47 protein stability using:

  • Cycloheximide chase assays to measure protein half-life

  • Co-localization studies with lysosomal markers

  • Flow cytometry to quantify cell surface versus intracellular CD47 expression ratios

• RAGA-CD47 interaction studies:

  • Co-immunoprecipitation assays to detect physical interactions

  • Proximity ligation assays to visualize protein interactions in situ

  • Domain mapping experiments to identify interaction regions

• Phagocytosis assays: Quantify the functional impact of RAGA deficiency on phagocytic clearance of cancer cells:

  • In vitro macrophage co-culture systems

  • Flow cytometry-based phagocytosis quantification

  • Time-lapse microscopy of phagocytic events

• Combined CD47 blockade and RAGA manipulation: Research has shown that RAGA deficiency promotes tumor growth due to CD47 accumulation, but also sensitizes tumors to CD47 blockade therapy . Design experiments that:

  • Combine RAGA knockdown with anti-CD47 antibody treatment

  • Measure tumor growth and macrophage infiltration

  • Analyze patient survival based on RAGA and CD47 expression profiles

How can researchers effectively implement antibody arrays for studying RRAGA/RRAGB expression and post-translational modifications?

Antibody arrays offer advantages for multiplexed protein measurements from small sample volumes. For RRAGA/RRAGB studies:

• Array design considerations:

  • Include antibodies targeting both total RRAGA/RRAGB and their phosphorylated forms

  • Include antibodies against known interaction partners in the mTOR pathway

  • Incorporate controls for assessing cross-reactivity and specificity

• Detection of glycosylation and other post-translational modifications:

  • Combine protein-specific antibodies with glycan-binding reagents

  • Use multimerization to improve the binding strength of glycan-binding reagents

  • Implement low-volume arrays to reduce sample consumption

• Optimization protocol:

  • Test multiple antibody concentrations (typically 50-200 μg/mL)

  • Optimize blocking conditions to minimize background

  • Validate with recombinant proteins and known positive/negative controls

  • Consider sandwich-based detection for improved sensitivity

• Data analysis approaches:

  • Normalize signals to internal control spots

  • Use appropriate statistical methods for multiplexed data

  • Validate findings with orthogonal methods (Western blot, mass spectrometry)

What are the best practices for utilizing retrieval-augmented diffusion models for RRAGA/RRAGB antibody optimization?

Recent advances in generative models have enhanced rational antibody design. For researchers looking to optimize RRAGA/RRAGB antibodies:

• Structure-informed retrieval mechanisms:

  • Identify structural homologous motifs that align with query structural constraints

  • Integrate exemplar motifs with the input backbone through dual-branch denoising modules

  • Utilize both structural and evolutionary information for optimization

• Conditional diffusion model implementation:

  • Iteratively refine the optimization process

  • Incorporate both global context and local evolutionary conditions

  • Consider model-agnostic approaches that can work with various generative frameworks

• Empirical validation strategies:

  • Test antibody performance in multiple inverse folding and optimization tasks

  • Compare to state-of-the-art performance metrics

  • Validate structural predictions with experimental binding assays

• Antigen mutation analysis:

  • Analyze how antigen mutations might disrupt antibody binding

  • Identify critical hotspot residues versus other positions

  • Assess the relative importance of changes in attractive versus repulsive energies

These approaches have demonstrated state-of-the-art performance in multiple antibody optimization tasks, offering new perspectives for biomolecular generative models .

How should researchers interpret conflicting data regarding RRAGA function in different cellular contexts?

RRAGA functions vary across cell types, creating challenges in data interpretation. To address conflicting observations:

• Cell type-specific analysis:

  • RRAGA shows distinct functions in microglia versus other cell types

  • In microglia, RRAGA regulates lysosomal function and development

  • In cancer cells, RRAGA affects CD47 expression and immune evasion

  • In B cells, oncogenic RagC mutations enhance activation and contribute to follicular lymphoma

• Developmental stage considerations:

  • Maternal contribution of RRAGA mRNA affects early developmental stages

  • Zygotic RRAGA mutants show normal morphology but have specific microglia defects

  • RRAGA mutants typically survive to 12 dpf in zebrafish models, indicating temporal-specific functions

• Experimental design for resolving conflicts:

  • Use conditional knockout systems for tissue-specific deletion

  • Implement temporal control of gene expression/deletion

  • Combine in vitro and in vivo approaches

  • Perform comprehensive phosphoproteomics to map signaling networks

• Systematic analysis of RagA versus RagC mutations:

  • RagC mutations (S74C and T89N) enhance germinal center formation and antibody production

  • RagA activating mutations show different effects than RagC mutations

  • Consider differential sensitivity of cell types to varying degrees of pathway activation